Publications by authors named "Paglialunga Luca"

Claim this Profile
G
Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer.
Enrico Caliman, Maria Cristina Petrella, Virginia Rossi, Francesca Mazzoni, Anna Maria Grosso, Luca Paglialunga

Curr Cancer Drug Targets· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients.
Sara Fancelli, Giandomenico Roviello, Francesca Castiglione, Enrico Caliman, Mazzoni Francesca, Paglialunga Luca

Curr Pharm Biotechnol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.
Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Luca Paglialunga, Marta Rita Gatta Michelet, Luca Voltolini

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Enrico Caliman, Sara Fancelli, Carlotta Ottanelli, Francesca Mazzoni, Luca Paglialunga, Luca Voltolini

Cancer Treat Res Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New options on the horizon for nononcogene addicted non-small-cell lung cancer.
Luca Paglialunga, Serena Ricciardi, Manolo D'Arcangelo

Future Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.
Biagio Ricciuti, Sara Baglivo, Luca Paglialunga, Andrea De Giglio, Guido Bellezza

Ther Adv Med Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
Biagio Ricciuti, Giulio Metro, Sara Baglivo, Daniela Colabrese, Rita Chiari, Luca Paglialunga

J Thorac Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Luca Paglialunga, Zena Salih, Biagio Ricciuti, Raffaele Califano

ESMO Open· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting EGFR and ALK in NSCLC: current evidence and future perspective.
Chiara Bennati, Luca Paglialunga, Biagio Ricciuti, Giulio Metro, Luca Marcomigni

Lung Cancer Manag· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
Biagio Ricciuti, Giulia Costanza Leonardi, Giulio Metro, Francesco Grignani, Luca Paglialunga

Expert Rev Respir Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy.
Biagio Ricciuti, Clelia Mencaroni, Luca Paglialunga, Francesco Paciullo, Lucio Crinò

Med Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma.
Melina Verso, Rita Chiari, Stefano Mosca, Laura Franco, Matthias Fischer, Luca Paglialunga

Thromb Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Rita Chiari, Giulio Metro, Daniela Iacono, Guido Bellezza, Alberto Rebonato, Luca Paglialunga

Lung Cancer· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.
Biagio Ricciuti, Carmen Mecca, Matteo Cenci, Giulia Costanza Leonardi, Lorenzo Perrone, Luca Paglialunga

Ecancermedicalscience· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis